Skip to main content

Advertisement

SpringerLink
Log in

Genome Editing for the Study of Cardiovascular Diseases

  • Regenerative Medicine (SM Wu, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The opportunities afforded through the recent advent of genome-editing technologies have allowed investigators to more easily study a number of diseases. The advantages and limitations of the most prominent genome-editing technologies are described in this review, along with potential applications specifically focused on cardiovascular diseases.

Recent Findings

The recent genome-editing tools using programmable nucleases, such as zinc-finger nucleases, transcription activator-like effector nucleases, and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (Cas9), have rapidly been adapted to manipulate genes in a variety of cellular and animal models. A number of recent cardiovascular disease-related publications report cases in which specific mutations are introduced into disease models for functional characterization and for testing of therapeutic strategies.

Summary

Recent advances in genome-editing technologies offer new approaches to understand and treat diseases. Here, we discuss genome editing strategies to easily characterize naturally occurring mutations and offer strategies with potential clinical relevance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6–245. doi:10.1161/CIR.0b013e31828124ad.

    Article  PubMed  Google Scholar 

  2. Kay MA. State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet. 2011;12(5):316–28. doi:10.1038/nrg2971.

    Article  CAS  PubMed  Google Scholar 

  3. Vaishnaw AK, Gollob J, Gamba-Vitalo C, Hutabarat R, Sah D, Meyers R, et al. A status report on RNAi therapeutics. Silence. 2010;1(1):14. doi:10.1186/1758-907X-1-14.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Cox DB, Platt RJ, Zhang F. Therapeutic genome editing: prospects and challenges. Nat Med. 2015;21(2):121–31. doi:10.1038/nm.3793.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Powell SK, Rivera-Soto R, Gray SJ. Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy. Discov Med. 2015;19(102):49–57.

    PubMed  PubMed Central  Google Scholar 

  6. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature. 2009;457(7228):426–33. doi:10.1038/nature07758.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Tiemann K, Rossi JJ. RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med. 2009;1(3):142–51. doi:10.1002/emmm.200900023.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov. 2010;9(1):57–67. doi:10.1038/nrd3010.

    Article  CAS  PubMed  Google Scholar 

  9. West SC. Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol. 2003;4(6):435–45. doi:10.1038/nrm1127.

    Article  CAS  PubMed  Google Scholar 

  10. Chu VT, Weber T, Wefers B, Wurst W, Sander S, Rajewsky K, et al. Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells. Nat Biotechnol. 2015;33(5):543–8. doi:10.1038/nbt.3198.

    Article  CAS  PubMed  Google Scholar 

  11. Lin S, Staahl BT, Alla RK, Doudna JA. Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery. Elife. 2014;3:e04766. doi:10.7554/eLife.04766.

    PubMed  PubMed Central  Google Scholar 

  12. Richardson CD, Ray GJ, DeWitt MA, Curie GL, Corn JE. Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA. Nat Biotechnol. 2016;34(3):339–44. doi:10.1038/nbt.3481.

    Article  CAS  PubMed  Google Scholar 

  13. Grizot S, Smith J, Daboussi F, Prieto J, Redondo P, Merino N, et al. Efficient targeting of a SCID gene by an engineered single-chain homing endonuclease. Nucleic Acids Res. 2009;37(16):5405–19. doi:10.1093/nar/gkp548.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Suzuki K, Mitsui K, Aizawa E, Hasegawa K, Kawase E, Yamagishi T, et al. Highly efficient transient gene expression and gene targeting in primate embryonic stem cells with helper-dependent adenoviral vectors. Proc Natl Acad Sci U S A. 2008;105(37):13781–6. doi:10.1073/pnas.0806976105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Khan IF, Hirata RK, Wang PR, Li Y, Kho J, Nelson A, et al. Engineering of human pluripotent stem cells by AAV-mediated gene targeting. Mol Ther. 2010;18(6):1192–9. doi:10.1038/mt.2010.55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010;11(9):636–46. doi:10.1038/nrg2842.

    Article  CAS  PubMed  Google Scholar 

  17. Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, Kim KA, et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol. 2007;25(11):1298–306. doi:10.1038/nbt1353.

    Article  CAS  PubMed  Google Scholar 

  18. Moehle EA, Rock JM, Lee YL, Jouvenot Y, DeKelver RC, Gregory PD, et al. Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases. Proc Natl Acad Sci U S A. 2007;104(9):3055–60. doi:10.1073/pnas.0611478104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Ramirez CL, Foley JE, Wright DA, Muller-Lerch F, Rahman SH, Cornu TI, et al. Unexpected failure rates for modular assembly of engineered zinc fingers. Nat Methods. 2008;5(5):374–5. doi:10.1038/nmeth0508-374.

    Article  CAS  PubMed  Google Scholar 

  20. Moscou MJ, Bogdanove AJ. A simple cipher governs DNA recognition by TAL effectors. Science. 2009;326(5959):1501. doi:10.1126/science.1178817.

    Article  CAS  PubMed  Google Scholar 

  21. Boch J, Scholze H, Schornack S, Landgraf A, Hahn S, Kay S, et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science. 2009;326(5959):1509–12. doi:10.1126/science.1178811.

    Article  CAS  PubMed  Google Scholar 

  22. Cermak T, Doyle EL, Christian M, Wang L, Zhang Y, Schmidt C, et al. Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 2011;39(12):e82. doi:10.1093/nar/gkr218.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD, Joung JK. FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol. 2012;30(5):460–5. doi:10.1038/nbt.2170.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Tsai SQ, Wyvekens N, Khayter C, Foden JA, Thapar V, Reyon D, et al. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol. 2014;32(6):569–76. doi:10.1038/nbt.2908.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Miller JC, Zhang L, Xia DF, Campo JJ, Ankoudinova IV, Guschin DY, et al. Improved specificity of TALE-based genome editing using an expanded RVD repertoire. Nat Methods. 2015;12(5):465–71. doi:10.1038/nmeth.3330.

    Article  CAS  PubMed  Google Scholar 

  26. Bultmann S, Morbitzer R, Schmidt CS, Thanisch K, Spada F, Elsaesser J, et al. Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers. Nucleic Acids Res. 2012;40(12):5368–77. doi:10.1093/nar/gks199.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Kim Y, Kweon J, Kim A, Chon JK, Yoo JY, Kim HJ, et al. A library of TAL effector nucleases spanning the human genome. Nat Biotechnol. 2013;31(3):251–8. doi:10.1038/nbt.2517.

    Article  CAS  PubMed  Google Scholar 

  28. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819–23. doi:10.1126/science.1231143.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339(6121):823–6. doi:10.1126/science.1232033.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J. RNA-programmed genome editing in human cells. Elife. 2013;2:e00471. doi:10.7554/eLife.00471.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Cho SW, Kim S, Kim JM, Kim JS. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol. 2013;31(3):230–2. doi:10.1038/nbt.2507.

    Article  CAS  PubMed  Google Scholar 

  32. Hou Z, Zhang Y, Propson NE, Howden SE, Chu LF, Sontheimer EJ, et al. Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc Natl Acad Sci U S A. 2013;110(39):15644–9. doi:10.1073/pnas.1313587110.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Esvelt KM, Mali P, Braff JL, Moosburner M, Yaung SJ, Church GM. Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat Methods. 2013;10(11):1116–21. doi:10.1038/nmeth.2681.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature. 2015;520(7546):186–91. doi:10.1038/nature14299.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Hirano H, Gootenberg JS, Horii T, Abudayyeh OO, Kimura M, Hsu PD, et al. Structure and Engineering of Francisella novicida Cas9. Cell. 2016;164(5):950–61. doi:10.1016/j.cell.2016.01.039.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Kleinstiver BP, Prew MS, Tsai SQ, Topkar VV, Nguyen NT, Zheng Z, et al. Engineered CRISPR-Cas9 nucleases with altered PAM specificities. Nature. 2015;523(7561):481–5. doi:10.1038/nature14592.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Zhang Y, Ge X, Yang F, Zhang L, Zheng J, Tan X, et al. Comparison of non-canonical PAMs for CRISPR/Cas9-mediated DNA cleavage in human cells. Sci Rep. 2014;4:5405. doi:10.1038/srep05405.

    PubMed  PubMed Central  Google Scholar 

  38. Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell. 2013;154(6):1380–9. doi:10.1016/j.cell.2013.08.021.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Mali P, Aach J, Stranges PB, Esvelt KM, Moosburner M, Kosuri S, et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol. 2013;31(9):833–8. doi:10.1038/nbt.2675.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Guilinger JP, Thompson DB, Liu DR. Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat Biotechnol. 2014;32(6):577–82. doi:10.1038/nbt.2909.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally engineered Cas9 nucleases with improved specificity. Science. 2016;351(6268):84–8. doi:10.1126/science.aad5227.

    Article  CAS  PubMed  Google Scholar 

  42. Fu Y, Sander JD, Reyon D, Cascio VM, Joung JK. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol. 2014;32(3):279–84. doi:10.1038/nbt.2808.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature. 2016;529(7587):490–5. doi:10.1038/nature16526.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. • Wang G, McCain ML, Yang L, He A, Pasqualini FS, Agarwal A, et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat Med. 2014;20(6):616–23. doi:10.1038/nm.3545. This study was one of the first to use genome editing in human pluripotent stem cells for the purpose of cardiovascuar disease modeling.

  45. Hinson JT, Chopra A, Nafissi N, Polacheck WJ, Benson CC, Swist S, et al. HEART DISEASE. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science. 2015;349(6251):982–6. doi:10.1126/science.aaa5458.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Karakikes I, Stillitano F, Nonnenmacher M, Tzimas C, Sanoudou D, Termglinchan V, et al. Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nat Commun. 2015;6:6955. doi:10.1038/ncomms7955.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. • Ding Q, Lee YK, Schaefer EA, Peters DT, Veres A, Kim K, et al. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell. 2013;12(2):238–51. doi:10.1016/j.stem.2012.11.011. This study was one of the first to use genome editing in human pluripotent stem cells for the purpose of cardiovascuar disease modeling.

  48. Maetzel D, Sarkar S, Wang H, Abi-Mosleh L, Xu P, Cheng AW, et al. Genetic and chemical correction of cholesterol accumulation and impaired autophagy in hepatic and neural cells derived from Niemann-Pick Type C patient-specific iPS cells. Stem Cell Rep. 2014;2(6):866–80. doi:10.1016/j.stemcr.2014.03.014.

    Article  CAS  Google Scholar 

  49. Gupta RM, Meissner TB, Cowan CA, Musunuru K. Genome-edited human pluripotent stem cell-derived macrophages as a model of reverse cholesterol transport—brief report. Arterioscler Thromb Vasc Biol. 2016;36(1):15–8. doi:10.1161/ATVBAHA.115.305956.

    CAS  PubMed  Google Scholar 

  50. Theodoris CV, Li M, White MP, Liu L, He D, Pollard KS, et al. Human disease modeling reveals integrated transcriptional and epigenetic mechanisms of NOTCH1 haploinsufficiency. Cell. 2015;160(6):1072–86. doi:10.1016/j.cell.2015.02.035.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Wang Y, Liang P, Lan F, Wu H, Lisowski L, Gu M, et al. Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing. J Am Coll Cardiol. 2014;64(5):451–9. doi:10.1016/j.jacc.2014.04.057.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Zhang M, D’Aniello C, Verkerk AO, Wrobel E, Frank S, Ward-van Oostwaard D, et al. Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and Lange-Nielsen syndrome: disease mechanisms and pharmacological rescue. Proc Natl Acad Sci U S A. 2014;111(50):E5383–92. doi:10.1073/pnas.1419553111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. • Wang H, Yang H, Shivalila CS, Dawlaty MM, Cheng AW, Zhang F, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 2013;153(4):910–8. doi:10.1016/j.cell.2013.04.025. This study established the high degree of efficacy of CRISPR/Cas9 in mouse embryos, foreshadowing its efficacy in embryos from a wide variety of species.

  54. Yang H, Wang H, Shivalila CS, Cheng AW, Shi L, Jaenisch R. One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell. 2013;154(6):1370–9. doi:10.1016/j.cell.2013.08.022.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Jacob HJ, Lazar J, Dwinell MR, Moreno C, Geurts AM. Gene targeting in the rat: advances and opportunities. Trends Genet. 2010;26(12):510–8. doi:10.1016/j.tig.2010.08.006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Moreno C, Hoffman M, Stodola TJ, Didier DN, Lazar J, Geurts AM, et al. Creation and characterization of a renin knockout rat. Hypertension. 2011;57(3):614–9. doi:10.1161/HYPERTENSIONAHA.110.163840.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Endres BT, Priestley JR, Palygin O, Flister MJ, Hoffman MJ, Weinberg BD, et al. Mutation of Plekha7 attenuates salt-sensitive hypertension in the rat. Proc Natl Acad Sci U S A. 2014;111(35):12817–22. doi:10.1073/pnas.1410745111.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Larcher T, Lafoux A, Tesson L, Remy S, Thepenier V, Francois V, et al. Characterization of dystrophin deficient rats: a new model for Duchenne muscular dystrophy. PLoS One. 2014;9(10):e110371. doi:10.1371/journal.pone.0110371.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Li J, Xie D, Huang J, Lv F, Shi D, Liu Y, et al. Cold-inducible RNA-binding protein regulates cardiac repolarization by targeting transient outward potassium channels. Circ Res. 2015;116(10):1655–9. doi:10.1161/CIRCRESAHA.116.306287.

    Article  CAS  PubMed  Google Scholar 

  60. Zhu X, Fang J, Jiang DS, Zhang P, Zhao GN, Zhu X, et al. Exacerbating pressure overload-induced cardiac hypertrophy: novel role of adaptor molecule Src homology 2-B3. Hypertension. 2015;66(3):571–81. doi:10.1161/HYPERTENSIONAHA.115.05183.

    Article  CAS  PubMed  Google Scholar 

  61. Yang D, Xu J, Zhu T, Fan J, Lai L, Zhang J, et al. Effective gene targeting in rabbits using RNA-guided Cas9 nucleases. J Mol Cell Biol. 2014;6(1):97–9. doi:10.1093/jmcb/mjt047.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Ji D, Zhao G, Songstad A, Cui X, Weinstein EJ. Efficient creation of an APOE knockout rabbit. Transgenic Res. 2015;24(2):227–35. doi:10.1007/s11248-014-9834-8.

    Article  CAS  PubMed  Google Scholar 

  63. Niimi M, Yang D, Kitajima S, Ning B, Wang C, Li S, et al. ApoE knockout rabbits: a novel model for the study of human hyperlipidemia. Atherosclerosis. 2016;245:187–93. doi:10.1016/j.atherosclerosis.2015.12.002.

    Article  CAS  PubMed  Google Scholar 

  64. Wang Y, Du Y, Shen B, Zhou X, Li J, Liu Y, et al. Efficient generation of gene-modified pigs via injection of zygote with Cas9/sgRNA. Sci Rep. 2015;5:8256. doi:10.1038/srep08256.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Umeyama K, Watanabe K, Watanabe M, Horiuchi K, Nakano K, Kitashiro M, et al. Generation of heterozygous fibrillin-1 mutant cloned pigs from genome-edited foetal fibroblasts. Sci Rep. 2016;6:24413. doi:10.1038/srep24413.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Ota S, Hisano Y, Ikawa Y, Kawahara A. Multiple genome modifications by the CRISPR/Cas9 system in zebrafish. Genes Cells. 2014;19(7):555–64. doi:10.1111/gtc.12154.

    Article  CAS  PubMed  Google Scholar 

  67. Kotani H, Taimatsu K, Ohga R, Ota S, Kawahara A. Efficient multiple genome modifications induced by the crRNAs, tracrRNA and Cas9 protein complex in zebrafish. PLoS One. 2015;10(5):e0128319. doi:10.1371/journal.pone.0128319.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Cao J, Navis A, Cox BD, Dickson AL, Gemberling M, Karra R, et al. Single epicardial cell transcriptome sequencing identifies Caveolin 1 as an essential factor in zebrafish heart regeneration. Development. 2016;143(2):232–43. doi:10.1242/dev.130534.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Rossi A, Kontarakis Z, Gerri C, Nolte H, Holper S, Kruger M, et al. Genetic compensation induced by deleterious mutations but not gene knockdowns. Nature. 2015;524(7564):230–3. doi:10.1038/nature14580.

    Article  CAS  PubMed  Google Scholar 

  70. Novodvorsky P, Watson O, Gray C, Wilkinson RN, Reeve S, Smythe C, et al. klf2ash317 mutant zebrafish do not recapitulate morpholino-induced vascular and haematopoietic phenotypes. PLoS One. 2015;10(10):e0141611. doi:10.1371/journal.pone.0141611.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Zou J, Tran D, Baalbaki M, Tang LF, Poon A, Pelonero A, et al. An internal promoter underlies the difference in disease severity between N- and C-terminal truncation mutations of Titin in zebrafish. Elife. 2015;4:e09406. doi:10.7554/eLife.09406.

    Article  PubMed  PubMed Central  Google Scholar 

  72. • Ding Q, Strong A, Patel KM, Ng SL, Gosis BS, Regan SN, et al. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res. 2014;115(5):488–92. doi:10.1161/CIRCRESAHA.115.304351. This study established the high degree of efficacy of CRISPR/Cas9 in the mouse liver.

  73. Yin H, Song CQ, Dorkin JR, Zhu LJ, Li Y, Wu Q, et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol. 2016;34(3):328–33. doi:10.1038/nbt.3471.

    Article  CAS  PubMed  Google Scholar 

  74. Muruve DA. The innate immune response to adenovirus vectors. Hum Gene Ther. 2004;15(12):1157–66. doi:10.1089/hum.2004.15.1157.

    Article  CAS  PubMed  Google Scholar 

  75. Gregory SM, Nazir SA, Metcalf JP. Implications of the innate immune response to adenovirus and adenoviral vectors. Futur Virol. 2011;6(3):357–74. doi:10.2217/fvl.11.6.

    Article  CAS  Google Scholar 

  76. Themis M, Waddington SN, Schmidt M, von Kalle C, Wang Y, Al-Allaf F, et al. Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol Ther. 2005;12(4):763–71. doi:10.1016/j.ymthe.2005.07.358.

    Article  CAS  PubMed  Google Scholar 

  77. Platt RJ, Chen S, Zhou Y, Yim MJ, Swiech L, Kempton HR, et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell. 2014;159(2):440–55. doi:10.1016/j.cell.2014.09.014.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Carroll KJ, Makarewich CA, McAnally J, Anderson DM, Zentilin L, Liu N, et al. A mouse model for adult cardiac-specific gene deletion with CRISPR/Cas9. Proc Natl Acad Sci U S A. 2016;113(2):338–43. doi:10.1073/pnas.1523918113.

    Article  CAS  PubMed  Google Scholar 

  79. Truong DJ, Kuhner K, Kuhn R, Werfel S, Engelhardt S, Wurst W, et al. Development of an intein-mediated split-Cas9 system for gene therapy. Nucleic Acids Res. 2015;43(13):6450–8. doi:10.1093/nar/gkv601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Chew WL, Tabebordbar M, Cheng JK, Mali P, Wu EY, Ng AH, et al. A multifunctional AAV-CRISPR-Cas9 and its host response. Nat Methods. 2016;13(10):868–74. doi:10.1038/nmeth.3993.

    Article  CAS  PubMed  Google Scholar 

  81. Seidah NG. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies. Curr Pharm Des. 2013;19(17):3161–72.

    Article  CAS  PubMed  Google Scholar 

  82. Lambert G, Charlton F, Rye KA, Piper DE. Molecular basis of PCSK9 function. Atherosclerosis. 2009;203(1):1–7. doi:10.1016/j.atherosclerosis.2008.06.010.

    Article  CAS  PubMed  Google Scholar 

  83. Poirier S, Mayer G, Poupon V, McPherson PS, Desjardins R, Ly K, et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem. 2009;284(42):28856–64. doi:10.1074/jbc.M109.037085.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Cohen JC, Boerwinkle E, Mosley Jr TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264–72. doi:10.1056/NEJMoa054013.

    Article  CAS  PubMed  Google Scholar 

  85. Shan L, Pang L, Zhang R, Murgolo NJ, Lan H, Hedrick JA. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem Biophys Res Commun. 2008;375(1):69–73. doi:10.1016/j.bbrc.2008.07.106.

    Article  CAS  PubMed  Google Scholar 

  86. Duff CJ, Scott MJ, Kirby IT, Hutchinson SE, Martin SL, Hooper NM. Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J. 2009;419(3):577–84. doi:10.1042/BJ20082407.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. Ni YG, Condra JH, Orsatti L, Shen X, Di Marco S, Pandit S, et al. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J Biol Chem. 2010;285(17):12882–91. doi:10.1074/jbc.M110.113035.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Graham MJ, Lemonidis KM, Whipple CP, Subramaniam A, Monia BP, Crooke ST, et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res. 2007;48(4):763–7. doi:10.1194/jlr.C600025-JLR200.

    Article  CAS  PubMed  Google Scholar 

  89. Wang X, Raghavan A, Chen T, Qiao L, Zhang Y, Ding Q, et al. CRISPR-Cas9 targeting of PCSK9 in human hepatocytes in vivo-brief report. Arterioscler Thromb Vasc Biol. 2016;36(5):783–6. doi:10.1161/ATVBAHA.116.307227.

    Article  CAS  PubMed  Google Scholar 

  90. Jiang J, Wakimoto H, Seidman JG, Seidman CE. Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy. Science. 2013;342(6154):111–4. doi:10.1126/science.1236921.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Yang Y, Wang L, Bell P, McMenamin D, He Z, White J, et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat Biotechnol. 2016;34(3):334–8. doi:10.1038/nbt.3469.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. •• Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014;370(10):901–10. doi:10.1056/NEJMoa1300662. This was the first clinical trial to demonstrate the efficacy of therapeutic genome editing in human patients.

Download references

Author information

Authors and Affiliations

  1. Cardiovascular Institute, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

    Alexandra C. Chadwick & Kiran Musunuru

  2. Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA

    Kiran Musunuru

Authors
  1. Alexandra C. Chadwick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kiran Musunuru
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kiran Musunuru.

Ethics declarations

Conflict of Interest

Alexandra Chadwick and Kiran Musunuru declare they have no conflicts of interest.

Human and Animal Rights and Informed Consent

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.

Additional information

This article is part of the Topical Collection on Regenerative Medicine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chadwick, A.C., Musunuru, K. Genome Editing for the Study of Cardiovascular Diseases. Curr Cardiol Rep 19, 22 (2017). https://doi.org/10.1007/s11886-017-0830-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-017-0830-5

Keywords

Search

Navigation